They’re the next new thing in cancer immunotherapy, but will bispecifics help more patients than CAR-Ts?

Wednesday, February 27, 2019

Stat News – Called bispecific antibodies, they’re being developed by some two dozen companies large and small, with a version cleverly branded as BiTEs already constituting 60 percent of Amgen’s oncology pipeline.